Aik Choon Tan
Overview
Explore the profile of Aik Choon Tan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
142
Citations
4208
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tarhini A, Hedges D, Tan A, Rodriguez P, Sukrithan V, Ratan A, et al.
J Oncol Res Ther
. 2025 Mar;
9(2).
PMID: 40083977
Purpose: The promise of immune checkpoint inhibitor (ICI) therapy underlines the importance of comprehensively investigating the rationale for combinations with diverse immune modulators across different cancer types. Given the progress...
2.
Eljilany I, Coleman S, Tan A, McCarter M, Carpten J, Colman H, et al.
Cells
. 2024 Dec;
13(23).
PMID: 39682743
Solid tumors vary by the immunogenic potential of the tumor microenvironment (TME) and the likelihood of response to immunotherapy. The emerging literature has identified key immune cell populations that significantly...
3.
Quandt Z, Jacob S, Fadlullah M, Wu C, Wu C, Huppert L, et al.
BJC Rep
. 2024 Nov;
2(1):46.
PMID: 39516257
Objective: Many patients with melanoma treated with immune checkpoint inhibitors (ICIs) do not derive response. Preclinical and retrospective studies identified that inhibition of the cyclooxygenase (COX) pathway may improve response...
4.
Hu M, Coleman S, Judson-Torres R, Tan A
Pigment Cell Melanoma Res
. 2024 Jul;
37(6):854-863.
PMID: 39072997
Gene expression profiling technologies have revolutionized cell biology, enabling researchers to identify gene signatures linked to various biological attributes of melanomas, such as pigmentation status, differentiation state, proliferative versus invasive...
5.
Dravillas C, Coleman 4th S, Hoyd R, Caryotakis G, Denko L, Chan C, et al.
Cancer Res Commun
. 2024 Jul;
4(8):1978-1990.
PMID: 39015091
Significance: We analyzed the tumor microbiome and interactions with genes and pathways in metastatic melanoma treated with immunotherapy and identified several microbes associated with immunotherapy response and immune-related gene expression...
6.
Saba N, Steuer C, Ekpenyong A, McCook-Veal A, Magliocca K, Patel M, et al.
Nat Med
. 2024 Jul;
30(8):2373.
PMID: 38956200
No abstract available.
7.
Fadlullah M, Lin C, Coleman S, Young A, Naqash A, Hu-Lieskovan S, et al.
Oncologist
. 2024 Feb;
29(5):415-421.
PMID: 38330451
Purpose: Immune checkpoint inhibitors (ICIs) have significantly improved the survival of patients with cancer and provided long-term durable benefit. However, ICI-treated patients develop a range of toxicities known as immune-related...
8.
Kerepesi C, Abushukair H, Ricciuti B, Nassar A, Adib E, Alessi J, et al.
JCO Precis Oncol
. 2024 Feb;
8:e2300439.
PMID: 38330262
Purpose: Recent evidence has shown that higher tumor mutational burden strongly correlates with an increased risk of immune-related adverse events (irAEs). By using an integrated multiomics approach, we further studied...
9.
Wang C, Ma A, Li Y, McNutt M, Zhang S, Zhu J, et al.
Cancer Res Commun
. 2024 Jan;
4(2):293-302.
PMID: 38259095
Significance: Studying the tumor microbiome in high-throughput sequencing data is challenging because of the extremely sparse data matrices, heterogeneity, and high likelihood of contamination. We present a new deep learning...
10.
Chemotherapy and Immune Checkpoint Blockade for Gastric and Gastroesophageal Junction Adenocarcinoma
Manji G, Lee S, Del Portillo A, May M, Ana S, Alouani E, et al.
JAMA Oncol
. 2023 Oct;
9(12):1702-1707.
PMID: 37856106
Importance: Combining immune checkpoint blockade (ICB) with chemotherapy improves outcomes in patients with metastatic gastric and gastroesophageal junction (G/GEJ) adenocarcinoma; however, whether this combination has activity in the perioperative setting...